|
| New mechanistic insights into modifiable risk factors that promote pancreatic cancer |
|
https://doi.org/10.18632/oncotarget.26813
|
| 2417-2418 |
|
| Do tumor cells escape from natural killer cell cytotoxicity by mimicking dendritic cells |
|
https://doi.org/10.18632/oncotarget.26815
|
| 2419-2420 |
|
| Prediction of onset of remnant gastric cancer by promoter DNA methylation of CDO1/HOPX/Reprimo/E-cadherin |
|
https://doi.org/10.18632/oncotarget.26814
Keita Kojima, Naoko Minatani, Hideki Ushiku, Satoru Ishii, Toshimichi Tanaka, Keigo Yokoi, Nobuyuki Nishizawa, Yosuke Ooizumi, Kazuharu Igarashi, Kei Hosoda, Hiromitsu Moriya, Hiroaki Mieno, Masahiko Watanabe, Keishi Yamashita
|
| 2423-2434 |
|
| Development and characterization of a cancer cachexia model employing a rare human duodenal neuroendocrine carcinomaoriginating cell line |
|
https://doi.org/10.18632/oncotarget.26764
|
| 2435-2450 |
|
| <sup>177</sup>LuPSMA radioligand therapy of predominant lymph node metastatic prostate cancer |
|
https://doi.org/10.18632/oncotarget.26789
|
| 2451-2461 |
|
| Sarcomas in the United States: Recent trends and a call for improved staging |
|
https://doi.org/10.18632/oncotarget.26809
|
| 2462-2474 |
|
| Plasma RANKL levels are not associated with breast cancer risk in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers |
|
https://doi.org/10.18632/oncotarget.26810
|
| 2475-2483 |
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß